Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 9/20 | 0.83 |
| ▸ | MAOB | P27338 | 9/20 | 0.83 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | ADH5 | P11766 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2640253 | 1.00 | MAOA (0.83) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Maleic Acid SCHEMBL2640251 | 1.00 | MAOA (0.83) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Fumaric Acid SCHEMBL27852077 | 1.00 | MAOA (0.83) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Fumaric Acid SCHEMBL2640692 | 0.99 | MAOA (0.81) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Maleic Acid SCHEMBL2640690 | 0.99 | MAOA (0.81) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Oxalic Acid SCHEMBL27852318 | 0.92 | MAOA (0.88) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Oxalic Acid SCHEMBL2640532 | 0.92 | MAOA (0.88) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| SCHEMBL936291 | 0.91 | MAOA (1.00) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| SCHEMBL29623853 | 0.91 | MAOA (1.00) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Water SCHEMBL2640298 | 0.90 | MAOA (0.97) | MAOAMAOBCYP11B1CYP11B2NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174966-B2 | Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline | ROTTAPHARM S.P.A. (IT) | 2015-11-03 | — | — | US | claimed |
| US-20120142713-A1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-06-07 | — | — | US | claimed |
| EP-2438058-A2 | CRYSTALLINE FORMS OF 6- ( 1H- IMIDAZOL- 1-YL) -2-PHENYLQUINAZOLINE AND SALTS THEREOF | Rottapharm S.p.A. (IT) | 2012-04-11 | — | — | EP | claimed |
| WO-2010140139-A2 | CRYSTALLINE FORMS OF 6- ( 1H- IMIDAZOL- 1-YL) -2-PHENYLQUINAZOLINE AND SALTS THEREOF | ROTTAPHARM S.P.A. (IT) | 2010-12-09 | — | — | WO | claimed |
| EP-2438058-B1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | Rottapharm Biotech Srl (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-9174966-B2 | Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline | ROTTAPHARM S.P.A. (IT) | 2015-11-03 | — | — | US | disclosed |
| US-20120142713-A1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-06-07 | — | — | US | disclosed |
| EP-2438058-A2 | CRYSTALLINE FORMS OF 6- ( 1H- IMIDAZOL- 1-YL) -2-PHENYLQUINAZOLINE AND SALTS THEREOF | Rottapharm S.p.A. (IT) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010140139-A2 | CRYSTALLINE FORMS OF 6- ( 1H- IMIDAZOL- 1-YL) -2-PHENYLQUINAZOLINE AND SALTS THEREOF | ROTTAPHARM S.P.A. (IT) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142713-A1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | ABCG2, CYP3A5, RCC1 | MEN1 2911/4885KMT2A 3326/4885MAOA 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.